From 3d67c57e5da0951de11f35c393a4c8955bd6b1d4 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:11:10 +0000 Subject: [PATCH 1/5] =?UTF-8?q?source:=202025-06-25-jacc-cvd-mortality-tre?= =?UTF-8?q?nds-us-1999-2023-yan.md=20=E2=86=92=20processed?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Pentagon-Agent: Epimetheus --- .../2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md | 5 ++++- 1 file changed, 4 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md (97%) diff --git a/inbox/queue/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md b/inbox/archive/health/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md similarity index 97% rename from inbox/queue/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md rename to inbox/archive/health/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md index 5c55c2a9b..b99ce0d3c 100644 --- a/inbox/queue/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md +++ b/inbox/archive/health/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md @@ -7,9 +7,12 @@ date: 2025-06-25 domain: health secondary_domains: [] format: research-paper -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-03 priority: high tags: [cardiovascular-disease, mortality-trends, hypertension, heart-failure, ischemic-heart-disease, US-population, 1999-2023, belief-1, CVD-bifurcation] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content -- 2.45.2 From 82756859e7b82e5a635be33bb4f08d914ee664d6 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:09:16 +0000 Subject: [PATCH 2/5] leo: extract claims from 2025-05-20-who-pandemic-agreement-adoption-us-withdrawal - Source: inbox/queue/2025-05-20-who-pandemic-agreement-adoption-us-withdrawal.md - Domain: grand-strategy - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Leo --- ...ception-as-proven-by-pabs-annex-dispute.md | 17 ++++++++ ...erests-override-catastrophic-death-toll.md | 17 ++++++++ .../grand-strategy/who-pandemic-agreement.md | 39 +++++++++++++++++++ 3 files changed, 73 insertions(+) create mode 100644 domains/grand-strategy/commercial-interests-blocking-condition-operates-continuously-through-ratification-not-just-at-governance-inception-as-proven-by-pabs-annex-dispute.md create mode 100644 domains/grand-strategy/pandemic-agreement-confirms-maximum-triggering-event-produces-broad-adoption-without-powerful-actor-participation-because-strategic-interests-override-catastrophic-death-toll.md create mode 100644 entities/grand-strategy/who-pandemic-agreement.md diff --git a/domains/grand-strategy/commercial-interests-blocking-condition-operates-continuously-through-ratification-not-just-at-governance-inception-as-proven-by-pabs-annex-dispute.md b/domains/grand-strategy/commercial-interests-blocking-condition-operates-continuously-through-ratification-not-just-at-governance-inception-as-proven-by-pabs-annex-dispute.md new file mode 100644 index 000000000..628b2ebd8 --- /dev/null +++ b/domains/grand-strategy/commercial-interests-blocking-condition-operates-continuously-through-ratification-not-just-at-governance-inception-as-proven-by-pabs-annex-dispute.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: grand-strategy +description: The WHO Pandemic Agreement PABS dispute (pathogen access vs. vaccine profit sharing) demonstrates that commercial alignment requirements persist through implementation phases, not just initial adoption +confidence: experimental +source: WHO Article 31, CEPI, Human Rights Watch analysis +created: 2026-04-03 +title: Commercial interests blocking condition operates continuously through ratification, not just at governance inception, as proven by PABS annex dispute +agent: leo +scope: structural +sourcer: Multiple sources (WHO, Human Rights Watch, CEPI, KFF) +related_claims: ["technology-governance-coordination-gaps-close-when-four-enabling-conditions-are-present-visible-triggering-events-commercial-network-effects-low-competitive-stakes-at-inception-or-physical-manifestation.md", "aviation-governance-succeeded-through-five-enabling-conditions-all-absent-for-ai.md"] +--- + +# Commercial interests blocking condition operates continuously through ratification, not just at governance inception, as proven by PABS annex dispute + +The WHO Pandemic Agreement was adopted May 2025 but remains unopened for signature as of April 2026 due to the PABS (Pathogen Access and Benefit Sharing) annex dispute. Article 31 stipulates the agreement opens for signature only after the PABS annex is adopted. The PABS dispute is a commercial interests conflict: wealthy nations need pathogen samples for vaccine R&D, developing nations want royalties and access to vaccines developed using those pathogens. This represents a textbook commercial blocking condition—not national security concerns, but profit distribution disputes. The critical insight is temporal: the agreement achieved adoption (120 countries voted YES), but commercial interests block the path from adoption to ratification. This challenges the assumption that commercial alignment is only required at governance inception. Instead, commercial interests operate as a continuous blocking condition through every phase: inception, adoption, signature, ratification, and implementation. The Montreal Protocol succeeded because commercial interests aligned at ALL phases (CFC substitutes were profitable). The Pandemic Agreement fails at the signature phase because vaccine profit distribution cannot be resolved. This suggests governance frameworks must maintain commercial alignment continuously, not just achieve it once at inception. diff --git a/domains/grand-strategy/pandemic-agreement-confirms-maximum-triggering-event-produces-broad-adoption-without-powerful-actor-participation-because-strategic-interests-override-catastrophic-death-toll.md b/domains/grand-strategy/pandemic-agreement-confirms-maximum-triggering-event-produces-broad-adoption-without-powerful-actor-participation-because-strategic-interests-override-catastrophic-death-toll.md new file mode 100644 index 000000000..bfa655d38 --- /dev/null +++ b/domains/grand-strategy/pandemic-agreement-confirms-maximum-triggering-event-produces-broad-adoption-without-powerful-actor-participation-because-strategic-interests-override-catastrophic-death-toll.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: grand-strategy +description: The WHO Pandemic Agreement (120 countries, 5.5 years post-COVID) confirms that even 7M+ deaths cannot force participation from actors whose strategic interests conflict with governance constraints +confidence: experimental +source: WHO, White House Executive Order 14155, multiple sources +created: 2026-04-03 +title: Maximum triggering events produce broad international adoption without powerful actor participation because strategic interests override catastrophic death toll +agent: leo +scope: structural +sourcer: Multiple sources (WHO, Human Rights Watch, CEPI, KFF) +related_claims: ["technology-governance-coordination-gaps-close-when-four-enabling-conditions-are-present-visible-triggering-events-commercial-network-effects-low-competitive-stakes-at-inception-or-physical-manifestation.md", "triggering-event-architecture-requires-three-components-infrastructure-disaster-champion-as-confirmed-by-pharmaceutical-and-arms-control-cases.md"] +--- + +# Maximum triggering events produce broad international adoption without powerful actor participation because strategic interests override catastrophic death toll + +The WHO Pandemic Agreement adoption (May 2025) provides canonical evidence for the triggering event principle's limits. COVID-19 caused 7M+ documented deaths globally, representing one of the largest triggering events in modern history. This produced broad international adoption: 120 countries voted YES, 11 abstained, 0 voted NO at the World Health Assembly. However, the United States—the most powerful actor in pandemic preparedness and vaccine development—formally withdrew from WHO (January 2026) and explicitly rejected the agreement. Executive Order 14155 states actions to effectuate the agreement 'will have no binding force on the United States.' This confirms a structural pattern: triggering events can produce broad consensus among actors whose behavior doesn't need governing, but cannot compel participation from the actors whose behavior most needs constraints. The US withdrawal strategy (exit rather than veto-and-negotiate) represents a harder-to-overcome pattern than traditional blocking. The agreement remains unopened for signature as of April 2026 due to the PABS commercial dispute, confirming that commercial interests remain the blocking condition even after adoption. This case establishes that catastrophic death toll (7M+) is insufficient to override strategic interests when governance would constrain frontier capabilities. diff --git a/entities/grand-strategy/who-pandemic-agreement.md b/entities/grand-strategy/who-pandemic-agreement.md new file mode 100644 index 000000000..456baf973 --- /dev/null +++ b/entities/grand-strategy/who-pandemic-agreement.md @@ -0,0 +1,39 @@ +# WHO Pandemic Agreement + +## Overview +The WHO Pandemic Agreement is an international treaty adopted by the World Health Assembly on May 20, 2025, designed to improve global pandemic preparedness and response. It was negotiated in response to the COVID-19 pandemic. + +## Status +- **Adopted:** May 20, 2025 (120 countries voted YES, 11 abstained, 0 voted NO) +- **Signature status:** NOT YET OPEN FOR SIGNATURE as of April 2026 +- **Blocking condition:** PABS (Pathogen Access and Benefit Sharing) annex must be adopted before signature opens (Article 31) +- **Entry into force:** Requires ratification by 60 countries, 30 days after 60th ratification + +## Key Provisions +- Pathogen Access and Benefit Sharing (PABS) framework +- Pandemic preparedness coordination +- Vaccine access and distribution mechanisms + +## Notable Exclusions +- **United States:** Withdrew from WHO via Executive Order 14155 (January 20, 2025), formally left January 22, 2026 +- US explicitly rejected the agreement and 2024 IHR amendments + +## Commercial Dispute +The PABS annex governs: +- **Wealthy nations:** Need pathogen samples for vaccine R&D +- **Developing nations:** Want royalties and access to vaccines developed using those pathogens + +This commercial interests dispute blocks the path from adoption to ratification. + +## Timeline +- **Late 2019** — COVID-19 outbreak begins +- **May 20, 2025** — Agreement adopted by World Health Assembly (5.5 years post-outbreak) +- **April 2026** — Still not open for signature due to PABS dispute (6+ years post-outbreak) +- **May 2026** — PABS annex expected to be negotiated at 79th World Health Assembly + +## Sources +- WHO official announcement (May 20, 2025) +- White House Executive Order 14155 +- Human Rights Watch analysis +- CEPI explainer +- KFF coverage \ No newline at end of file -- 2.45.2 From 91dbfbe607889b061e51794e28ce247fd0f7a71e Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:11:37 +0000 Subject: [PATCH 3/5] =?UTF-8?q?source:=202025-10-xx-california-ab489-ai-he?= =?UTF-8?q?althcare-disclosure-2026.md=20=E2=86=92=20processed?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Pentagon-Agent: Epimetheus --- ...5-10-xx-california-ab489-ai-healthcare-disclosure-2026.md | 5 ++++- 1 file changed, 4 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md (97%) diff --git a/inbox/queue/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md b/inbox/archive/health/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md similarity index 97% rename from inbox/queue/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md rename to inbox/archive/health/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md index e53a9e39c..a3b453b66 100644 --- a/inbox/queue/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md +++ b/inbox/archive/health/2025-10-xx-california-ab489-ai-healthcare-disclosure-2026.md @@ -7,9 +7,12 @@ date: 2025-10-23 domain: health secondary_domains: [ai-alignment] format: legal-analysis -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-03 priority: medium tags: [California, AB-3030, AB-489, clinical-AI, disclosure, regulation, state-legislation, federal-model, belief-5] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content -- 2.45.2 From a6ccac4dfef9ffb3d0f092d6b878703b9a552e4e Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:11:56 +0000 Subject: [PATCH 4/5] =?UTF-8?q?source:=202025-12-01-who-glp1-global-guidel?= =?UTF-8?q?ine-obesity-treatment.md=20=E2=86=92=20null-result?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Pentagon-Agent: Epimetheus --- .../2025-12-01-who-glp1-global-guideline-obesity-treatment.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) rename inbox/{queue => null-result}/2025-12-01-who-glp1-global-guideline-obesity-treatment.md (98%) diff --git a/inbox/queue/2025-12-01-who-glp1-global-guideline-obesity-treatment.md b/inbox/null-result/2025-12-01-who-glp1-global-guideline-obesity-treatment.md similarity index 98% rename from inbox/queue/2025-12-01-who-glp1-global-guideline-obesity-treatment.md rename to inbox/null-result/2025-12-01-who-glp1-global-guideline-obesity-treatment.md index 3c19066ee..c72571ce2 100644 --- a/inbox/queue/2025-12-01-who-glp1-global-guideline-obesity-treatment.md +++ b/inbox/null-result/2025-12-01-who-glp1-global-guideline-obesity-treatment.md @@ -7,9 +7,10 @@ date: 2025-12-01 domain: health secondary_domains: [] format: policy-document -status: unprocessed +status: null-result priority: medium tags: [WHO, GLP-1, obesity, global-guideline, equity, adherence, long-term-safety, belief-1, belief-2] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content -- 2.45.2 From 4b518fd2407fddf6a1f668cef5cbd169cbdc9c43 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:11:08 +0000 Subject: [PATCH 5/5] vida: extract claims from 2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan - Source: inbox/queue/2025-06-25-jacc-cvd-mortality-trends-us-1999-2023-yan.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...3-becoming-leading-contributing-cvd-cause.md | 17 +++++++++++++++++ ...-baseline-despite-acute-care-improvements.md | 17 +++++++++++++++++ 2 files changed, 34 insertions(+) create mode 100644 domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md create mode 100644 domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md diff --git a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md new file mode 100644 index 000000000..bf3a71441 --- /dev/null +++ b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: Hypertensive disease AAMR increased from 15.8 to 31.9 per 100,000 (1999-2023), driven by obesity, sedentary behavior, and treatment gaps that pharmacological acute care cannot address +confidence: proven +source: Yan et al., JACC 2025, CDC WONDER database 1999-2023 +created: 2026-04-03 +title: Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden +agent: vida +scope: causal +sourcer: Yan et al. / JACC +related_claims: ["[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"] +--- + +# Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden + +The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical. diff --git a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md new file mode 100644 index 000000000..37c53a08d --- /dev/null +++ b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: Heart failure AAMR declined from 20.3 (1999) to 16.9 (2011) then rose to 21.6 (2023), the highest recorded value, because patients saved from MI survive with underlying metabolic risk +confidence: proven +source: Yan et al., JACC 2025, CDC WONDER database 1999-2023 +created: 2026-04-03 +title: US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden +agent: vida +scope: causal +sourcer: Yan et al. / JACC +related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"] +--- + +# US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden + +The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes. -- 2.45.2